FDA Releases Final Guidance on Institutional Review Board Continuing Review After Clinical Investigation Approval

Summary

The Food and Drug Administration (FDA) has finalized a guidance document to help institutional review boards (IRBs) conduct continuing reviews of clinical investigations, ensuring the protection of human subjects and upholding the rights and welfare of those involved in the studies.